Option chain shows key data for Aptose Biosciences's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Aptose Biosciences.

Aptose Biosciences (NASDAQ:APTO) Stock, Option Chain

Aptose Biosciences

Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AMIX

APTO

ATPC

BJDX

CYCC

FCUV

GRFX

PIXY

PMNT

POLA

SHLS

SIFY

STAF

TOVX

ZBAO

Why Zhibao Technology Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket

wall-street-ai17

Earnings

MOMO

SPWH

Hello Group, Zscaler And 3 Stocks To Watch Heading Into Tuesday

Penny Stocks

Small Cap

AREB

CISS

CVKD

IFRX

Intelligent Bio Solutions Inc. - Common Stock

INBS

INTC

JAGX

KLAC

ONCO

REVB

TCBP

TELL

VMAR

WLGS

YIBO

Shares of  Tellurian Inc. (NASDAQ: TELL) shares rose sharply in pre-market trading following a report suggesting the company hired Lazard to explore a possible sale.

Tellurian shares jumped 16.3% to $0.6050 in pre-market trading

Why Tellurian Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket

Aptose Biosciences Inc

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group Ltd

Aptos - United States Dollar

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains Aptose Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) with a Buy and lowers the price target from $7 to $2.

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Buy on Aptose Biosciences, Lowers Price Target to $2

Aptose Biosciences Announced Initiation Of The TUSCANY Study, Tuspetinib In Combination Therapy With Azacitidine And Venetoclax As A Frontline Triplet Combination Therapy For Patients Newly Diagnosed With Acute Myeloid Leukemia

Aptose Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(1.19) by 68.91 percent.

Earnings Beats

Aptose Biosciences Q3 2024 GAAP EPS $(0.37) Beats $(1.19) Estimate

General

Aptose shares are trading higher after the company announced a $10 million loan through a Facility Agreement with Hanmi Pharmaceutical Co.

Shares of Zhibao Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBAO#NASDAQ">ZBAO</a>) rose sharply in today's pre-market trading after the company announced that it has won a tender to provide high-end medical third party administration services to the People&#8217;s<a href="https://www.benzinga.com/quote/ZBAO/news"> Insurance Company of China Limited.</a>
Zhibao Technology shares jumped 18.8% to $3.99 in the pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Sify Technologies Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>) gained 129.4% to $0.7599 in pre-market trading. Sify becomes first in India to achieve NVIDIA DGX-ready data center certification for liquid cooling to enable breakthrough AI performance.</li>
<li>Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) rose 48.1% to $0.6040 in today's pre-market trading after the company announced a $10 million loan through a Facility Agreement with Hanmi Pharmaceutical Co.</li>
<li>Conduit Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) gained 25.8% to $0.1549 in pre-market trading after declining over 5% on Friday.</li>
<li>Perfect Moment Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PMNT#NYSE">PMNT</a>) gained 25.2% to $1.29 in pre-market trading.</li>
<li>Cyclacel Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) gained 21.7% to $1.28 in pre-market trading.</li>
<li>Polar Power Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POLA#NASDAQ">POLA</a>) gained 18.8% to $0.47 in the pre-market trading session. Polar Power, last month, posted a profit for the second quarter.</li>
<li>QuantaSing Group Ltd- ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) gained 13.2% to $1.97 in pre-market trading.</li>
<li>Shoals Technologies Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) rose 11.5% to $6.01 in pre-market trading.</li>
<li>Autozi Internet Technology (Global) Ltd.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZI#NASDAQ">AZI</a>) gained 5% to $3.15 in pre-market trading amid post-IPO volatility.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Bluejay Diagnostics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) fell 13.3% to $0.16 in pre-market trading after declining around 6% on Friday.</li>
<li>Focus Universal Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCUV#NASDAQ">FCUV</a>) shares fell 13.1% to $0.2338 in pre-market trading. Focus Universal shares jumped over 41% on Friday after the company in a Form4 filing disclosed that CEO Desheng Wang bought 302,100 shares of stock at an average price of $0.18 per share.</li>
<li>Staffing 360 Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAF#NASDAQ">STAF</a>) shares declined 12.1% to $2.05 in pre-market trading.</li>
<li>Graphex Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRFX#NYSE">GRFX</a>) fell 12% to $0.21 in pre-market trading after surging 13% on Friday.</li>
<li>ShiftPixy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIXY#NASDAQ">PIXY</a>) shares fell 11.8% to $1.04 in pre-market trading. ShiftPixy recently announced the pricing of $2.5 million offering.</li>
<li>Agape ATP Corporation  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares declined 11.4% to $2.26 in pre-market trading after jumping 60% on Friday.</li>
<li>Autonomix Medical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) shares fell 10.9% to $0.60 in pre-market trading after jumping 14% on Friday.</li>
<li>Theriva Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#NASDAQ">TOVX</a>) fell 10% to $5.31 in today's pre-market trading after gaining over 25% on Friday.</li>
<li>United States Steel Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) shares dipped 5.8% to $35.70 in pre-market trading. Vice President Kamala Harris has expressed her support for American ownership of United States Steel, amidst ongoing foreign acquisition attempts.</li>
<li>Diversified Energy Company PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEC#NYSE">DEC</a>) declined 5.6% to $11.54 in pre-market trading. Keybanc analyst Tim Rezvan, last week, initiated coverage on Diversified Energy with an Overweight rating and announced a price target of $18.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40677064/this-analyst-with-87-accuracy-rate-sees-over-24-upside-in-nvidia-here-are-5-stock-picks-for-last-wee">This Analyst With 87% Accuracy Rate Sees Over 24% Upside In Nvidia &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

With U.S. stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Hello Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOMO#NASDAQ">MOMO</a>) to report quarterly earnings at 28 cents per share on revenue of $372.52 million before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Hello Group shares fell 0.6% to $6.60 in after-hours trading.</li>
<li>Analysts expect Zscaler, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) to post quarterly earnings at 69 cents per share on revenue of $567.93 million. The company will release earnings after the markets close. Zscaler shares gained 0.1% to $200.00 in after-hours trading.</li>
<li>Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) shares rose in Friday's after-hours trading after the company announced a $10 million loan through a Facility Agreement with Hanmi Pharmaceutical Co. Aptose shares jumped 69.3% to $0.6874 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>After the markets close, HealthEquity, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) is projected to post quarterly earnings at 70 cents per share on revenue of $284.87 million. HealthEquity shares fell 0.6% to $79.10 in the after-hours trading session.</li>
<li>Analysts expect Sportsman&#8217;s Warehouse Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWH#NASDAQ">SPWH</a>) to report a quarterly loss at 9 cents per share on revenue of $285.03 million after the closing bell. Sportsman&#8217;s Warehouse shares fell 1% to $2.08 in the after-hours trading session.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/08/40666406/top-2-real-estate-stocks-that-could-blast-off-this-quarter">Top 2 Real Estate Stocks That Could Blast Off This Quarter</a></li>
</ul>
Image generated using AI tools

WIIM

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>, TSX:<a class="ticker" href="https://www.benzinga.com/stock/APS#TSX">APS</a>), a clinical-stage precision oncology company developing tuspetinib, a highly differentiated oral kinase inhibitor for the treatment of patients with acute myeloid leukemia (AML), today announced that it received a $10 million loan through a Facility Agreement with Hanmi Pharmaceutical Co. Ltd. ("Hanmi"). The loan is convertible as prepayment of milestone obligations under the Future Collaboration Agreement (as defined hereinafter) or repayable after the expected completion of a triple drug combination trial with tuspetinib in newly diagnosed AML patients. Aptose will use the proceeds from such loan for the development of tuspetinib. &nbsp;
Beyond the $10 million Facility Agreement, Aptose and Hanmi have agreed to negotiate a new tuspetinib co-development collaboration agreement (the "Future Collaboration Agreement'), intended to provide additional funding to accelerate clinical development of tuspetinib. Aptose licensed tuspetinib from Hanmi Pharmaceutical in November 2021.

Contracts

TSX:APS

Aptose Biosciences Secures $10M Loan From Hanmi Pharmaceutical For Tuspetinib Development; Companies To Negotiate New Co-Development Agreement For AML Treatment

Aptose Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.86) by 50 percent.

Aptose Biosciences Q2 2024 GAAP EPS $(0.43) Beats $(0.86) Estimate

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Aptose Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) with a Buy and maintains $7 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Aptose Biosciences, Maintains $7 Price Target

<ul>
<li>TUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) and Differentiate TUS from other Investigational Drugs in AML</li>
</ul>
<ul>
<li>TUS Monotherapy and TUS+VEN Doublet Therapy Active in Difficult-to-treat Genetic Subgroups, FLT3 Wildtype AML</li>
</ul>
<ul>
<li>TUS Shown to Target VEN Resistance Mechanisms and Retain Activity on VEN-Resistant AML Cells in Preclinical Study</li>
</ul>
<ul>
<li>TUS+VEN+Azacitidine (AZA) Triplet Trial to Treat Newly Diagnosed AML Patients; Clinical Sites Being Activated</li>
</ul>

Aptose Showcases Clinical And Preclinical Results For Tuspetinib (TUS) At The 2024 EHA Hybrid Congress

<a href="https://www.zacks.com/stock/news/2288032/aptose-biosciences-apto-upgraded-to-buy-what-does-it-mean-for-the-stock" title="https://www.zacks.com/stock/news/2288032/aptose-biosciences-apto-upgraded-to-buy-what-does-it-mean-for-the-stock">https://www.zacks.com/stock/news/2288032/aptose-biosciences-apto-upgraded-to-buy-what-does-it-mean-for-the-stock</a>

Rumors

Aptose Biosciences Shares Move Higher; Traders Circulate Zacks Article Titled "Aptose Biosciences Upgraded to Buy: What Does It Mean for the Stock?"

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>, TSX:<a class="ticker" href="https://www.benzinga.com/stock/APS#TSX">APS</a>), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that it has entered into a definitive agreement for the issuance and sale of 3,855,000 of its common shares (or common share equivalents in lieu thereof) at a purchase price of $1.15 per share (or per common share equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. Additionally, in a concurrent private placement, Aptose has agreed to issue unregistered series A warrants to purchase up to 3,855,000 common shares and series B warrants to purchase up to 3,855,000 common shares, each at an exercise price of $1.15 per share. The unregistered warrants will be exercisable beginning on the effective date of shareholder approval of the issuance of the shares issuable upon exercise of the warrants. The series A warrants will expire five years from the date of shareholder approval and the series B warrants will expire eighteen months from the date of shareholder approval. The offering is expected to close on or about June 3, 2024, subject to the satisfaction of customary closing conditions. &nbsp;
H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.

Offerings

Aptose Announces $4.43M Registered Direct Offering Of 3.855M Shares Of Common Stock At A Price Of $1.15/Share, Priced At-the-Market Under Nasdaq Rules

Canaccord Genuity analyst John Newman maintains Aptose Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) with a Buy and lowers the price target from $15 to $6.

Canaccord Genuity Maintains Buy on Aptose Biosciences, Lowers Price Target to $6

Aptose Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.74) by 1.35 percent. This is a 67.56 percent increase over losses of $(2.25) per share from the same period last year.

Aptose Biosciences Q1 EPS $(0.73) Beats $(0.74) Estimate

Piper Sandler analyst Edward Tenthoff maintains Aptose Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) with a Overweight and maintains $5 price target.

Piper Sandler Maintains Overweight on Aptose Biosciences, Maintains $5 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains Aptose Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) with a Buy and maintains $23 price target.

HC Wainwright & Co. Maintains Buy on Aptose Biosciences, Maintains $23 Price Target

Aptose Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) reported quarterly losses of $(1.44) per share which beat the analyst consensus estimate of $(1.59) by 9.43 percent. This is a 12.73 percent increase over losses of $(1.65) per share from the same period last year.

Aptose Biosciences Q4 EPS $(1.44) Beats $(1.59) Estimate

Aptose Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) reported its Q4 earnings results on Tuesday, March 26, 2024 at 04:02 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Aptose Biosciences beat estimated earnings by 9.0%, reporting an EPS of $-1.44 versus an estimate of $-1.59.
Revenue was down $0 from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.29 which was followed by a 24.0% drop in the share price the next day.

To track all earnings releases for Aptose Biosciences <a href="https://www.benzinga.com/quote/APTO/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Aptose Biosciences Q4 Earnings

Aptose Reports FY23 Loss Per Share Of $(7.58) vs $(6.80) Loss Last Year

Warning: APTO is at high risk of performing badly

Aptose Biosciences (TSE:APS) has released an update. Aptose Biosciences is advancing the development of its promising drug tuspetinib as part of a ...

Aptose Biosciences Advances AML Triplet Therapy

Aptose Biosciences GAAP EPS of -$0.37 beats by $0.27

Aptose Biosciences ( ($APTO) ) has released its Q3 earnings. Here is a breakdown of the information Aptose Biosciences presented to its investors. ...

Aptose Biosciences Reports Q3 2024 Financial Highlights

Aptose Biosciences (APTO) announced initiation of the TUSCANY study, tuspetinib, TUS, in combination therapy with azacitidine, AZA, and venetoclax,...

Aptose Biosciences initiates TUSCANY Phase 1/2 study

H.C. Wainwright lowered the firm's price target on Aptose Biosciences (APTO) to $2 from $7 and keeps a Buy rating on the shares. The firm expects s...

Aptose Biosciences price target lowered to $2 from $7 at H.C. Wainwright

Press Releases

Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress

Aptose Announces Results from Annual and Special Meeting of Shareholders

Aptose Announces Receipt of Deficiency Notice from Nasdaq

Biotech

NodThera Announces Appointment of Greg Chow as Chief Financial and Business Officer

Aptose Reports Results for the Second Quarter 2024

Aptose Announces Adjournment of its Special Meeting of Shareholders

Financing

Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib

Comments

Aptose Biosciences

Aptose Biosciences (APTO) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga